Role of Epigenetics in Chronic Myeloid Leukemia

The efficacy of therapeutic modalities in chronic myeloid leukemia (CML) depends on both genetic and epigenetic mechanisms. This review focuses on epigenetic mechanisms involved in the pathogenesis of CML and in resistance of tumor cells to tyrosine kinase inhibitors leading to the leukemic clone escape and propagation. Regulatory events at the levels of gene regulation by transcription factors and microRNAs are discussed in the context of CML pathogenesis and therapeutic modalities.

• Publication year

  2013

• Venue

  Current Hematologic Malignancy Reports

• Publication date

  2013-01-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s11899-012-0152-zPMID 23296408PMCID 3578734
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Downregulation of Mir-31, Mir-155, and Mir-564 in Chronic Myeloid Leukemia Cells

  2012influential reference
• Aberrant methylation in promoter-associated CpG islands of multiple genes in chronic myelogenous leukemia blast crisis.

  2012cited by this paper
• Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia.

  2012influential reference
• miRNA-451: A putative predictor marker of Imatinib therapy response in chronic myeloid leukemia.

  2012cited by this paper
• Epigenetics and blood disorders

  2012cited by this paper
• A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies

  2012cited by this paper
• Enhancing miRNA annotation confidence in miRBase by continuous cross dataset analysis

  2011cited by this paper
• Chromatin mechanisms regulating gene expression in health and disease.

  2011cited by this paper
• BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.

  2011cited by this paper
• Aberrant DNA Methylation Is Associated with Disease Progression, Resistance to Imatinib and Shortened Survival in Chronic Myelogenous Leukemia

  2011cited by this paper
• Expression patterns of microRNAs associated with CML phases and their disease related targets

  2011cited by this paper
• MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML

  2011cited by this paper
• miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.

  2010cited by this paper
• Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia

  2010cited by this paper
• DNA Methylation Profiles and Their Relationship with Cytogenetic Status in Adult Acute Myeloid Leukemia

  2010cited by this paper
• Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia

  2010influential reference
• Methylation status of DDIT3 gene in Chronic Myeloid Leukemia

  2010cited by this paper
• A Genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers

  2010cited by this paper
• Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial

  2010cited by this paper
• Deactylase inhibition in myeloproliferative neoplasms

  2010cited by this paper
• MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations

  2009cited by this paper
• Methylation status of RASSF1A in patients with chronic myeloid leukemia.

  2009cited by this paper
• Aberrant methylation of the death‐associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia

  2009cited by this paper
• Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

  2009influential reference
• Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression.

  2008cited by this paper
• Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis.

  2008cited by this paper
• Down-Regulation of hsa-miR-10a in Chronic Myeloid Leukemia CD34+ Cells Increases USF2-Mediated Cell Growth

  2008cited by this paper
• FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

  2007cited by this paper
• Phase II study of low‐dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia

  2007cited by this paper
• Histone deacetylases and cancer

  2007cited by this paper
• Inactivation of HOXA Genes by Hypermethylation in Myeloid and Lymphoid Malignancy is Frequent and Associated with Poor Prognosis

  2007cited by this paper
• Functions of site-specific histone acetylation and deacetylation.

  2007cited by this paper
• Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells.

  2007influential reference
• Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate–Sensitive or Imatinib Mesylate–Resistant Chronic Myelogenous Leukemia Cells

  2006cited by this paper
• Anticancer activities of histone deacetylase inhibitors

  2006cited by this paper
• A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer

  2006cited by this paper
• Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.

  2005cited by this paper
• Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

  2005cited by this paper
• INHIBITION OF HISTONE DEACETYLASE 6 ACETYLATES AND DISRUPTS THE CHAPERONE FUNCTION OF HEAT SHOCK PROTEIN 90: A NOVEL BASIS OF ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS

  2005cited by this paper
• Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development

  2005cited by this paper
• Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

  2004cited by this paper
• Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma

  2004cited by this paper
• Controlling the double helix

  2003cited by this paper
• Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.

  2003cited by this paper
• Results of decitabine (5‐aza‐2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

  2003cited by this paper
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• Methylation of the p15INK4B gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation

  2001influential reference
• Translating the Histone Code

  2001cited by this paper
• ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.

  2001cited by this paper
• RNA: Guiding Gene Silencing

  2001cited by this paper
• Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications.

  2000cited by this paper
• Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications.

  2000influential reference
• ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia.

  1999cited by this paper
• Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance.

  1999cited by this paper
• High-risk myelodysplastic syndromes and hypermethylation of the p15Ink4B gene.

  1998influential reference
• HIC1 hypermethylation is a late event in hematopoietic neoplasms.

  1997cited by this paper
• Molecular follow-up of disease progression and interferon therapy in chronic myelocytic leukemia.

  1997cited by this paper
• Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies.

  1997cited by this paper
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  1996cited by this paper
• The estrogen receptor CpG island is methylated in most hematopoietic neoplasms.

  1996cited by this paper
• Abnormal methylation of the calcitonin gene marks progression of chronic myelogenous leukemia.

  1991cited by this paper
• A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining

  1973cited by this paper
• DNA Contents of Chromosome Ph1 and Chromosome 21 in Human Chronic Granulocytic Leukemia

  1964cited by this paper
• A minute chromosome in human chronic granulocytic leukemia

  1960cited by this paper

• Beyond TKIs: Advancing Therapeutic Frontiers with Immunotherapy, Targeted Agents, and Combination Strategies in Resistant Chronic Myeloid Leukemia

  2025cites this paper
• Uncommon phenotypes of BCR::ABL1-positive chronic myelogenous leukemia

  2025cites this paper
• METHYLATION PATTERN OF THE RUNX3 GENE AND ITS IMPACT ON RESPONSE TO IMATINIB THERAPY IN CHRONIC MYELOID LEUKEMIA

  2023cites this paper
• Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.

  2023cites this paper
• The Downregulation of Both Giant HERCs, HERC1 and HERC2, Is an Unambiguous Feature of Chronic Myeloid Leukemia, and HERC1 Levels Are Associated with Leukemic Cell Differentiation

  2022cites this paper
• Identification of Key Histone Modifications and Their Regulatory Regions on Gene Expression Level Changes in Chronic Myelogenous Leukemia

  2021cites this paper
• Genetic Biomarkers in Chronic Myeloid Leukemia: What Have We Learned So Far?

  2021cites this paper
• Global identification of circular RNAs in imatinib (IM) resistance of chronic myeloid leukemia (CML) by modulating signaling pathways of circ_0080145/miR-203/ABL1 and circ 0051886/miR-637/ABL1

  2021cites this paper
• Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance

  2021cites this paper
• DNA Methylation and Intra-Clonal Heterogeneity: The Chronic Myeloid Leukemia Model

  2021cites this paper
• Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia

  2021cites this paper
• Polycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia Cells

  2021cites this paper
• The Superior Cytotoxicity of Dual Targeting of BCR/ABL and PI3K in K562 Cells: Proposing a Novel Therapeutic Potential for the Treatment of CML

  2021cites this paper
• MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers

  2020cites this paper
• Down-regulation of Protein Tyrosine Phosphatase Receptor Gamma (PTPRG) in Chronic Myeloid Leukemia Patients in The State of Qatar is Due to Aberrant DNA Methylation Mechanism

  2020cites this paper
• Aberrant DNA methylation of PTPRG as one possible mechanism of its under‐expression in CML patients in the State of Qatar

  2020cites this paper
• LncRNA Hmrhl regulates expression of cancer related genes in chronic myelogenous leukemia through chromatin association

  2020cites this paper
• When Oxidative Stress Meets Epigenetics: Implications in Cancer Development

  2020cites this paper
• Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML

  2019cites this paper
• Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients

  2018cites this paper
• Global identification of circular RNAs in chronic myeloid leukemia reveals hsa_circ_0080145 regulates cell proliferation by sponging miR-29b.

  2018cites this paper
• Epigenetic modifications in chronic myeloid leukemia cells through ruxolitinib treatment

  2018cites this paper
• Knockdown of NUDT21 inhibits proliferation and promotes apoptosis of human K562 leukemia cells through ERK pathway

  2018cites this paper
• Dysregulation of miR‐125b predicts poor response to therapy in pediatric acute lymphoblastic leukemia

  2018cites this paper
• Bcr‐Abl regulation of sphingomyelin synthase 1 reveals a novel oncogenic‐driven mechanism of protein up‐regulation

  2018cites this paper
• BCR–ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy

  2017influential citation
• Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options.

  2017cites this paper
• Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia

  2017cites this paper
• MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells

  2017cites this paper
• MiR-15a-5p negatively regulates cell survival and metastasis by targeting CXCL10 in chronic myeloid leukemia.

  2017cites this paper
• Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia

  2017cites this paper
• MiR-15 a-5 p negatively regulates cell survival and metastasis by targeting CXCL 10 in chronic myeloid leukemia

  2017cites this paper
• Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach

  2017influential citation
• In vitro evaluation of penta-O-galloyl-β-d-glucose (PGG) on miRNA expression and apoptosis in BCR-ABL+ ALL

  2017cites this paper
• Analysing DNA methylation signatures of cell identity

  2016cites this paper
• The mechanistic role of epigenetic in multiple myeloma

  2016cites this paper
• Tyrosine Kinase Inhibitors in Ph+ Chronic Myeloid Leukemia Therapy: a Review.

  2016cites this paper
• Is imatinib a prototypical example of targeted drug therapy?

  2016cites this paper
• The genetics of chronic myelogenous leukaemia

  2016cites this paper
• Molecular Mechanism of TKI Resistance and Potential Approaches to Overcome Resistance

  2016cites this paper
• The Genetic Basis of Haematological Cancers: Tosi/The Genetic Basis of Haematological Cancers

  2016cites this paper
• Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia

  2016cites this paper
• Role of miR-125b and miR-203 expressions in the pathogenesis of BCR-ABL+ Acute Lymphoblastic Leukemia (ALL)

  2016cites this paper
• CTNNA 1 promotor hypermethylation in chronic myeloid leukemia

  2016cites this paper
• Dissecting the role of aberrant DNA methylation in human leukemia

  2015cites this paper
• Impact of microRNA in Different Diseases and Cancer

  2015cites this paper
• DNA Methyltransferase 1 Drives Transcriptional Down‐Modulation of β Catenin Antagonist Chibby1 Associated With the BCR‐ABL1 Gene of Chronic Myeloid Leukemia

  2015cites this paper
• Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) in Chronic Myeloid Leukaemia

  2015cites this paper
• Epigenetic roots of immunologic disease and new methods for examining chromatin regulatory pathways

  2015cites this paper
• EXPRESSION LEVELS OF JAK/STAT SIGNALING GENES IN NEWLY DIAGNOSED, DRUG SENSITIVE AND RESISTANT CHRONIC MYELOID LEUKEMIA PATIENTS

  2015cites this paper
• The Implication of Cancer Progenitor Cells and the Role of Epigenetics in the Development of Novel Therapeutic Strategies for Chronic Myeloid Leukemia

  2015cites this paper
• Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms

  2014cites this paper
• DNA Methylation of SLC 5 A 8 , a Tumor Suppressor Gene in Chronic Myeloid Leukemia

  2014cites this paper
• Characterization of miRNomes in Acute and Chronic Myeloid Leukemia Cell Lines

  2014cites this paper
• MicroRNA-520a-5p displays a therapeutic effect upon chronic myelogenous leukemia cells by targeting STAT3 and enhances the anticarcinogenic role of capsaicin

  2014cites this paper
• Concise Review: Cancer Cells Escape from Oncogene Addiction: Understanding the Mechanisms Behind Treatment Failure for More Effective Targeting

  2014cites this paper
• Identification of nilotinib-altered microRNA expression patterns in imatinib-resistant chronic myeloid leukemia cells

  2013cites this paper
• Unravelling survival pathways: the road to next-generation chronic myeloid leukaemia drugs?

  2013cites this paper
• Identification and Characterization of FGF2-Dependent mRNA: microRNA Networks During Lens Fiber Cell Differentiation

  2013cites this paper
• A bioinformatics pipeline for sequence to structure: A case study with a Cml patient undergoing treatment with imatinib

  2013cites this paper